Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: Use with and without glucagon

J. J. Brown, J. R. Duncan, Jay Heiken, D. M. Balfe, A. P. Corr, S. A. Mirowitz, S. S. Eilenberg, J. K.T. Lee

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects (16 healthy volunteers and 14 patients). Transaxial T1-, proton density-, and T2-weighted MR images were acquired in each subject before and after the administration of PFOB. The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration. The degree of bowel marking, clarity of bowel-wall visualization, ability to distinguish bowel from adjacent parenchymal organs, and severity of phase-encoding artifacts were independently analyzed by two reviewers. Oral administration of PFOB significantly (P < .001) increased the percentage of bowel loops with low signal intensity. Subcutaneous administration of glucagon significantly (P < .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies. The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.

Original languageEnglish (US)
Pages (from-to)455-460
Number of pages6
JournalRadiology
Volume181
Issue number2
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Gastrointestinal Agents
Glucagon
Contrast Media
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Artifacts
Healthy Volunteers
Oral Administration
perflubron
Protons

Keywords

  • Contrast media, experimental studies
  • Gastrointestinal tract, MR studies
  • Glucagon
  • Magnetic resonance (MR), contrast enhancement
  • Perfluoroctylbromide

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Brown, J. J., Duncan, J. R., Heiken, J., Balfe, D. M., Corr, A. P., Mirowitz, S. A., ... Lee, J. K. T. (1991). Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: Use with and without glucagon. Radiology, 181(2), 455-460. https://doi.org/10.1148/radiology.181.2.1924788

Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging : Use with and without glucagon. / Brown, J. J.; Duncan, J. R.; Heiken, Jay; Balfe, D. M.; Corr, A. P.; Mirowitz, S. A.; Eilenberg, S. S.; Lee, J. K.T.

In: Radiology, Vol. 181, No. 2, 01.01.1991, p. 455-460.

Research output: Contribution to journalArticle

Brown, JJ, Duncan, JR, Heiken, J, Balfe, DM, Corr, AP, Mirowitz, SA, Eilenberg, SS & Lee, JKT 1991, 'Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: Use with and without glucagon', Radiology, vol. 181, no. 2, pp. 455-460. https://doi.org/10.1148/radiology.181.2.1924788
Brown, J. J. ; Duncan, J. R. ; Heiken, Jay ; Balfe, D. M. ; Corr, A. P. ; Mirowitz, S. A. ; Eilenberg, S. S. ; Lee, J. K.T. / Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging : Use with and without glucagon. In: Radiology. 1991 ; Vol. 181, No. 2. pp. 455-460.
@article{fd9a1d9aaf9d4a54ae5b2915fb369d45,
title = "Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: Use with and without glucagon",
abstract = "The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects (16 healthy volunteers and 14 patients). Transaxial T1-, proton density-, and T2-weighted MR images were acquired in each subject before and after the administration of PFOB. The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration. The degree of bowel marking, clarity of bowel-wall visualization, ability to distinguish bowel from adjacent parenchymal organs, and severity of phase-encoding artifacts were independently analyzed by two reviewers. Oral administration of PFOB significantly (P < .001) increased the percentage of bowel loops with low signal intensity. Subcutaneous administration of glucagon significantly (P < .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies. The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.",
keywords = "Contrast media, experimental studies, Gastrointestinal tract, MR studies, Glucagon, Magnetic resonance (MR), contrast enhancement, Perfluoroctylbromide",
author = "Brown, {J. J.} and Duncan, {J. R.} and Jay Heiken and Balfe, {D. M.} and Corr, {A. P.} and Mirowitz, {S. A.} and Eilenberg, {S. S.} and Lee, {J. K.T.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1148/radiology.181.2.1924788",
language = "English (US)",
volume = "181",
pages = "455--460",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

TY - JOUR

T1 - Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging

T2 - Use with and without glucagon

AU - Brown, J. J.

AU - Duncan, J. R.

AU - Heiken, Jay

AU - Balfe, D. M.

AU - Corr, A. P.

AU - Mirowitz, S. A.

AU - Eilenberg, S. S.

AU - Lee, J. K.T.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects (16 healthy volunteers and 14 patients). Transaxial T1-, proton density-, and T2-weighted MR images were acquired in each subject before and after the administration of PFOB. The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration. The degree of bowel marking, clarity of bowel-wall visualization, ability to distinguish bowel from adjacent parenchymal organs, and severity of phase-encoding artifacts were independently analyzed by two reviewers. Oral administration of PFOB significantly (P < .001) increased the percentage of bowel loops with low signal intensity. Subcutaneous administration of glucagon significantly (P < .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies. The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.

AB - The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects (16 healthy volunteers and 14 patients). Transaxial T1-, proton density-, and T2-weighted MR images were acquired in each subject before and after the administration of PFOB. The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration. The degree of bowel marking, clarity of bowel-wall visualization, ability to distinguish bowel from adjacent parenchymal organs, and severity of phase-encoding artifacts were independently analyzed by two reviewers. Oral administration of PFOB significantly (P < .001) increased the percentage of bowel loops with low signal intensity. Subcutaneous administration of glucagon significantly (P < .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies. The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.

KW - Contrast media, experimental studies

KW - Gastrointestinal tract, MR studies

KW - Glucagon

KW - Magnetic resonance (MR), contrast enhancement

KW - Perfluoroctylbromide

UR - http://www.scopus.com/inward/record.url?scp=0025999041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025999041&partnerID=8YFLogxK

U2 - 10.1148/radiology.181.2.1924788

DO - 10.1148/radiology.181.2.1924788

M3 - Article

C2 - 1924788

AN - SCOPUS:0025999041

VL - 181

SP - 455

EP - 460

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -